Intravenous extended infusion of recombinant human soluble thrombomodulin prevented tissue factor-induced disseminated intravascular coagulation in rats.
This study demonstrated that intravenous infusion of recombinant human soluble thrombomodulin (rhs-TM) could inhibit disseminated intravascular coagulation (DIC) caused by 4 hr infusion of tissue factor (TF) in rats. Extended infusion of TF reduced fibrinogen and platelet counts and elevated serum FDP level. Pretreatment and coinfusion of rhs-TM could block changes of these DIC-parameters without prolongation of APTT. Heparin, which is a potent anti-DIC drug, could also inhibit these changes with extra prolongation of APTT and PT. Thus, these results suggest thrombomodulin prevent DIC less bleeding tendency than heparin.
Mohri
M
M
Institute for Life Science Research, Asahi Chemical Industry Co., Ltd, Fuji.
Oka
M
M
Aoki
Y
Y
Gonda
Y
Y
Hirata
S
S
Gomi
K
K
Kiyota
T
T
Sugihara
T
T
Yamamoto
S
S
Ishida
T
T
D000818:Animals; D004195:Disease Models, Animal; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005353:Fibronectins / Q000097:blood; D006493:Heparin / Q000008:administration & dosage / Q000502:physiology; D007262:Infusions, Intravenous; D010314:Partial Thromboplastin Time; D010976:Platelet Count; D011517:Prothrombin Time; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D018180:Thrombomodulin / Q000378:metabolism; D013925:Thromboplastin / Q000009:adverse effects*
D005353:Fibronectins; D011994:Recombinant Proteins; D018180:Thrombomodulin; D006493:Heparin; D013925:Thromboplastin